UBS maintains DexCom at Buy, raises price target to $107 from $102

What happened

UBS maintained its Buy rating on DexCom and raised its price target to $107 from $102, a 4.9% increase. UBS said the new target implied 30.0% upside from DexCom’s October 30 closing price of $82.29. Recent analyst targets ranged from $85 to $120.

Confirmed

Global impact / market context

The higher target signals greater expected share value from UBS, but it does not change DexCom’s reported sales, costs, or cash available. If investors act on the more optimistic view, buying could support the share price; the target remains an analyst estimate, not a guaranteed outcome.

Analyst inference

Recent analyst opinions were mixed: the five listed targets ranged from $85 to $120, while ratings included Buy, Neutral, and Overweight. UBS’s $107 target sits within that range, so its increase adds an optimistic view without establishing a shared forecast.

Confirmed

What to watch

1. Watch for DexCom’s next reported business results and guidance, which can show whether sales and costs support expectations behind analysts’ share-price targets. Analyst inference
2. Compare any later analyst targets and ratings with UBS’s $107 target and the cited $85–$120 range to see whether views converge or diverge. Analyst inference
3. Track whether the company reports changes in revenue, costs, or cash available; the article provides no new operating figures to validate UBS’s higher target. Analyst inference

Evidence

• Original source link unavailable